Home | Welcome to Contract Pharma   
Last Updated Monday, May 25 2015


Financial Report: Alexion

By Gil Roth

Published January 30, 2014
Financial Report: Alexion 4Q13

4Q Revenues: $442 million (+38%)

4Q Loss: $19 million (earnings of $81 million in 4Q12)

FY Revenues: $1.6 billion (+37%)

FY Earnings: $253 million (-1%)

Comments: Sales of the company's sole commercial product, Soliris, continued to grow as it added new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion took a $153 million charge during FY13 in connection with centralizing certain business operations, impairment of intangible assets, expenses from license agreements, and an intellectual property settlement; $129 million of that was incurred in 4Q13, leading to a net loss.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On